摘要
当前新型冠状病毒肺炎(COVID-19)的治疗尚无特效药,国家医疗救治主管部门陆续发布多个针对COVID-19的诊疗方案。莪术油及其制剂在抗病毒、治疗肺纤维化等方面的疗效已被多项基础研究及临床应用所证实,推测在COVID-19的临床治疗中可试用莪术油注射液,特别是治疗肺间质改变造成的肺纤维化、促进止泻、减少患者发热时间等。此外,与抗病毒、抗生素等临床配伍使用的经验提示,莪术油注射液可用于减少COVID-19患者在治疗过程中药物引发性肝损伤,提高治疗效果。为莪术油及其制剂在协同治疗COVID-19中的科学使用提供理论依据。
Because of no specific drug for the treatment of coronavirus disease 2019(COVID-19), a number of treatment plans for COVID-19 had been released by national medical treatment authorities. The efficacy of zedoary turmeric oil and its preparation for antiviral and pulmonary fibrosis treatment had been confirmed by many basic studies and clinical applications. It was speculated that Zedoary Turmeric Oil Injection could be used in the clinical diagnose and treatment of COVID-19, especially in the treatment of pulmonary fibrosis caused by pulmonary interstitial changes, antidiarrheal and fever. In addition, the compatibility of Zedoary Turmeric Oil Injection with other antiviral and antibiotic drugs suggested that it could be used to reduce drug-induced liver injury in the treatment of COVID-19 patients, and improve the therapeutic effect, which provided a theoretical basis for the scientific use of zedoary turmeric oil and its injection in the treatment of COVID-19.
作者
姜程曦
郭月琴
张淑君
崔友
李晓祥
任仙樱
李校堃
鲍康德
JIANG Cheng-xi;GUO Yue-qin;ZHANG Shu-jun;CUI You;LI Xiao-xiang;REN Xian-ying;LI Xiao-kun;BAO Kang-de(College of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Institute of Life Sciences,Wenzhou University,Wenzhou 325035,China;Zhejiang Tianrui Pharmaceutical Co.,Ltd,Ruian 325200,China;Hefei Future Drug Development Co.,Ltd.,Hefei 230000,China;Zhejiang Collaborative Innovation Center of Biomedicines,Wenzhou 325035,China)
出处
《中草药》
CAS
CSCD
北大核心
2020年第11期3062-3069,共8页
Chinese Traditional and Herbal Drugs
基金
浙江大学新型冠状病毒肺炎(COVID-19)应急科研专项(2020XGZX029)
温州市新型冠状病毒肺炎疫情防控应急攻关项目(ZY202002)
合肥市未来药物开发有限公司莪术油注射液用于新型冠状病毒感染患者临床研究的配套技术服务横向课题(KJHX2004)。
作者简介
姜程曦(1971-),男,安徽青阳人,博士,研究员,研究方向为中药学。Tel:18969715696,E-mail:jiangchengxi@126.com;通信作者:李校堃(1964-),男,陕西富平人,博士生导师,中国工程院院士,研究方向为基因工程蛋白药物的基础研究、工程技术和新药研发、临床应用和转化医学研究。Tel:(0577)86699891,E-mail:xiaokunli@163.net;通信作者:鲍康德(1969-),男,安徽青阳人,博士,副教授,研究方向为中药学。Tel:15867176058,E-mail:bocand@163.com;并列第一作者:郭月琴(1994-),女,新疆乌苏人,硕士研究生。Tel:(0577)86699891。
